IB Net Payout Yields Model

Tilray: Same Tired Story


  • Tilray reported misleading revenue growth in FQ4 due to not comparing pro-forma revenue from the merger for the quarter.
  • The Canadian cannabis company is still struggling to grow due to lockdowns in Canada and Germany.
  • The stock trades at substantial premium P/S multiple while risks exist on a U.S. acquisition plan.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More »
Before the market open, Tilray (TLRYreported FQ4 results to provide the first quarterly results of the combined Aphria and Tilray operations. Unfortunately, the Canadian cannabis company failed to provide pro-forma numbers for the combination. My investment thesis remains Bearish on the stock after the 20% rally in early trading.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Update - July 30

The stock is down another 6% possibly on this news of not getting the votes for increasing authorized shares, though $TLRY suggests the issue is not getting enough people to vote which is a common issue with retail investors.

-today convened and then adjourned the Special Meeting of Stockholders intended to approve two shareholder proposals: (1) a proposal to increase the authorized number of shares of common stock (“Authorized Shares Proposal”); and (2) a number of governance enhancements to increase stockholder rights (the “Governance Proposals”). The Special Meeting was adjourned to August 19, 2021, at 11:00 a.m. Eastern Time.

Finviz Chart


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders